123 related articles for article (PubMed ID: 21365334)
1. Mass-spectrometric characterization of cisplatin binding sites on native and denatured ubiquitin.
Zhao T; King FL
J Biol Inorg Chem; 2011 Apr; 16(4):633-9. PubMed ID: 21365334
[TBL] [Abstract][Full Text] [Related]
2. A mass spectrometric comparison of the interactions of cisplatin and transplatin with myoglobin.
Zhao T; King FL
J Inorg Biochem; 2010 Feb; 104(2):186-92. PubMed ID: 19945168
[TBL] [Abstract][Full Text] [Related]
3. Interactions of cisplatin and transplatin with proteins. Comparison of binding kinetics, binding sites and reactivity of the Pt-protein adducts of cisplatin and transplatin towards biological nucleophiles.
Peleg-Shulman T; Najajreh Y; Gibson D
J Inorg Biochem; 2002 Jul; 91(1):306-11. PubMed ID: 12121789
[TBL] [Abstract][Full Text] [Related]
4. Direct determination of the primary binding site of cisplatin on cytochrome C by mass spectrometry.
Zhao T; King FL
J Am Soc Mass Spectrom; 2009 Jun; 20(6):1141-7. PubMed ID: 19286393
[TBL] [Abstract][Full Text] [Related]
5. Shape changes induced by N-terminal platination of ubiquitin by cisplatin.
Williams JP; Phillips HI; Campuzano I; Sadler PJ
J Am Soc Mass Spectrom; 2010 Jul; 21(7):1097-106. PubMed ID: 20227292
[TBL] [Abstract][Full Text] [Related]
6. Fragmentation methods on the balance: unambiguous top-down mass spectrometric characterization of oxaliplatin-ubiquitin binding sites.
Meier SM; Tsybin YO; Dyson PJ; Keppler BK; Hartinger CG
Anal Bioanal Chem; 2012 Mar; 402(8):2655-62. PubMed ID: 22065348
[TBL] [Abstract][Full Text] [Related]
7. High resolution mass spectrometry for studying the interactions of cisplatin with oligonucleotides.
Egger AE; Hartinger CG; Ben Hamidane H; Tsybin YO; Keppler BK; Dyson PJ
Inorg Chem; 2008 Nov; 47(22):10626-33. PubMed ID: 18947179
[TBL] [Abstract][Full Text] [Related]
8. Characterization of platinum anticancer drug protein-binding sites using a top-down mass spectrometric approach.
Hartinger CG; Tsybin YO; Fuchser J; Dyson PJ
Inorg Chem; 2008 Jan; 47(1):17-9. PubMed ID: 18067289
[TBL] [Abstract][Full Text] [Related]
9. Probing conformational changes of ubiquitin by host-guest chemistry using electrospray ionization mass spectrometry.
Lee JW; Heo SW; Lee SJ; Ko JY; Kim H; Kim HI
J Am Soc Mass Spectrom; 2013 Jan; 24(1):21-9. PubMed ID: 23247966
[TBL] [Abstract][Full Text] [Related]
10. Molecular Recognition of M1-Linked Ubiquitin Chains by Native and Phosphorylated UBAN Domains.
Herhaus L; van den Bedem H; Tang S; Maslennikov I; Wakatsuki S; Dikic I; Rahighi S
J Mol Biol; 2019 Aug; 431(17):3146-3156. PubMed ID: 31247202
[TBL] [Abstract][Full Text] [Related]
11. Versatile Tool for the Analysis of Metal-Protein Interactions Reveals the Promiscuity of Metallodrug-Protein Interactions.
Lee RFS; Menin L; Patiny L; Ortiz D; Dyson PJ
Anal Chem; 2017 Nov; 89(22):11985-11989. PubMed ID: 29053254
[TBL] [Abstract][Full Text] [Related]
12. Identification of binding sites of cisplatin to human copper chaperone protein Cox17 by high-resolution FT-ICR-MS.
Li L; Guo W; Wu K; Zhao Y; Luo Q; Zhang Q; Liu J; Xiong S; Wang F
Rapid Commun Mass Spectrom; 2016 Aug; 30 Suppl 1():168-72. PubMed ID: 27539433
[TBL] [Abstract][Full Text] [Related]
13. Top-down mass spectrometric approach for the full characterization of insulin-cisplatin adducts.
Moreno-Gordaliza E; Cañas B; Palacios MA; Gómez-Gómez MM
Anal Chem; 2009 May; 81(9):3507-16. PubMed ID: 19323565
[TBL] [Abstract][Full Text] [Related]
14. Mass spectrometric studies on the interaction of cisplatin and insulin.
Li J; Yue L; Liu Y; Yin X; Yin Q; Pan Y; Yang L
Amino Acids; 2016 Apr; 48(4):1033-1043. PubMed ID: 26724920
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of cisplatin binding sites in human serum proteins using hyphenated multidimensional liquid chromatography and ESI tandem mass spectrometry.
Will J; Wolters DA; Sheldrick WS
ChemMedChem; 2008 Nov; 3(11):1696-707. PubMed ID: 18855968
[TBL] [Abstract][Full Text] [Related]
16. Probing affinity and ubiquitin linkage selectivity of ubiquitin-binding domains using mass spectrometry.
Sokratous K; Roach LV; Channing D; Strachan J; Long J; Searle MS; Layfield R; Oldham NJ
J Am Chem Soc; 2012 Apr; 134(14):6416-24. PubMed ID: 22428841
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into interactions between ubiquitin specific protease 5 and its polyubiquitin substrates by mass spectrometry and ion mobility spectrometry.
Scott D; Layfield R; Oldham NJ
Protein Sci; 2015 Aug; 24(8):1257-63. PubMed ID: 25970461
[TBL] [Abstract][Full Text] [Related]
18. A mass spectrometric and molecular modelling study of cisplatin binding to transferrin.
Khalaila I; Allardyce CS; Verma CS; Dyson PJ
Chembiochem; 2005 Oct; 6(10):1788-95. PubMed ID: 16196027
[TBL] [Abstract][Full Text] [Related]
19. V-type nerve agents phosphonylate ubiquitin at biologically relevant lysine residues and induce intramolecular cyclization by an isopeptide bond.
Schmidt C; Breyer F; Blum MM; Thiermann H; Worek F; John H
Anal Bioanal Chem; 2014 Aug; 406(21):5171-85. PubMed ID: 24652148
[TBL] [Abstract][Full Text] [Related]
20. Ion mobility-mass spectrometry study of folded ubiquitin conformers induced by treatment with cis-[Pd(en)(H2O2]2+.
Giganti VG; Kundoor S; Best WA; Angel LA
J Am Soc Mass Spectrom; 2011 Feb; 22(2):300-9. PubMed ID: 21472589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
